Current Report Filing (8-k)
December 14 2017 - 5:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 14, 2017
Galena Biopharma, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-33958
|
|
20-8099512
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
2000 Crow Canyon Place, Suite 380
San Ramon, CA 94583
|
|
94583
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code: (855)
855-4253
Check the appropriate box below
if the
Form 8-K
filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
☒
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934 (§
240.12b-2
of this
chapter).
Emerging growth
company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.
☐
On December 14, 2017, Galena Biopharma, Inc. (Galena) issued a press
release entitled Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form
8-K
and is incorporated by reference herein.
Item 9.01.
|
Financial Statements and Exhibits.
|
Exhibit Index
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Galena Biopharma, Inc.
|
|
|
|
|
Dated: December 14, 2017
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Thomas J. Knapp
|
|
|
|
|
|
|
Thomas J. Knapp
Interim General
Counsel & Corporate Secretary
|
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024